Abstract 3936
Background
The Risk of Acute Deterioration (RAD) conceived as the patient status at risk for progression, with severe damage or life-threatening conditions, includes possible progression, emergence or recurrence of serious adverse-events Literature related with physiological parameters such blood pressure, cardiac or respiratory alterations and the capacity for a rapid identification of these RAD as predictors of preventable complications and adverse events The hematological patients with complex processes derived from his tumor, comorbidities and complexity hospitalized, may require admission to Iintensive care or unexpected death. Determine the patient profile that needs prevention and nursing activities and control for the risk of acute deterioration RAD at the centres of the Catalan Institute of Oncology-ICO, for 2018.
Methods
Retrospective multicenter cross-sectional study. Scope: 8 oncological units ICO-L’Hospitalet, ICO-Badalona and ICO-Girona. Data obtained from anonymized registries system of the electronic clinical history of patients.January to December of 2018.
Results
From 6.003 episodes of hospitalized patients, 2.661 contained an indicator of RAD as main nurse diagnostic on register, representing 44.3% of the cases. Observation and intensive surveillance or semi-intensive is fundamental. Nurses’ early identification of RAD and 39.06% needed intensive or semi-surveillance.Total deaths 10.68%. The registration of interventions: systematic control of mental state (77.09%); control of respiratory frequency in 29.14%; simultaneous recording of 5 vital signs (26.60%); 4 vital signs (82.16%); intake/out control (18.67%); record of diuresis (80.86%).
Conclusions
Nurses most performed and registered activities were control of heart rate, blood pressure, Sat. O2, temperature, diuresis and mind alert. Low registration for FR, despite being identified as a key intervention in the early identification of RAD and is omitted or is not registered although being prescribed in care plan. Early detection of physiological changes and the identification of patients RAD are need to provide adequate preventive care and treatment and to ensure continued evaluation that avoid deterioration or its consequences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract